Search
for
Sort by
Research 30 of 96
- Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
- A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma
- Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
- Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in Partial Response Despite Continuous Vismodegib Treatment
- Experiences with Smo antagonist vismodegib for the treatment of locally advanced basal cell carcinoma
- A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
- Targeting of Smoothened for therapeutic gain
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Emerging drugs and combination strategies for basal cell carcinoma
- From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Basal Cell Carcinoma, Hedgehog Signaling, and Targeted Therapeutics: The Long and Winding Road
- Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
- Hair loss and Hedgehog inhibitors: a class effect?
- Abstracts
- Malignant epithelial tumors: Part II. Therapy and prevention
- Scalp basal cell carcinoma: A different entity?
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- “Prick or treat”: a case of systemic reaction during intradermal tests with beta-lactams
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Cells to Surgery Quiz: December 2017
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors
- The HEDGEHOG-GLI1 pathway is important for fibroproliferative properties in keloids and as a candidate therapeutic target
- Keloid pathogenesis and fibroproliferative properties are dependent on stem cells regulated by the HEDGEHOG-GLI1 pathway
- Author response: Coordinated hedgehog signaling induces new hair follicles in adult skin